SOBI — Swedish Orphan Biovitrum AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK165.02bn
- SEK180.18bn
- SEK28.24bn
Brief: SOBI Receives Complete Response Letter From FDA For NASP
US FDA declines to approve Sobi's therapy for uncontrolled gout
Berenberg keeps Sobi at 'buy' on Altuvoct potential, sees sales guidance hike likely
Europe Research Roundup: BAT, GEA Group, Qiagen
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Brief: SOBI's Tryngolza Cuts Pancreatitis Risk By 85% In Study
Brief: Sweden's SOBI Says Positive Topline Results From Pivotal Phase 3 Reduce 2 Study Of Pozdeutinurad In Gout
Europe Research Roundup: Basic-Fit, ENI, Nexans
Sweden's SOBI Q1 revenue slightly beats estimates on immunology and hematology strength
Brief: Swedish Orphan Biovitrum Keeps Outlook 2026 Unchanged
Brief: MHRA Approves Olezarsen For Treatment Of Familial Chylomicronemia Syndrome
Brief: SOBI Receives Health Canada Approval For Empaveli® (Pegcetacoplan) For The Treatment Of C3g And Primary IC-Mpgn
Brief: SOBI: EMA Validates Indication Extension Application For Tryngolza (Olezarsen)
Brief: Results From Embrace Phase 2A Study Of Emapalumab In Interferon-Gamma-Driven Sepsis Presented At Isicem
Brief: SOBI Board Member Buys Sek 978,434 Of Shares On Feb 25
Europe Research Roundup: Airbus, Nestlé, VAR Energi
Brief: Swedish Orphan Biovitrum Targets SEK 55 Billion Revenue By 2030
Brief: Swedish Orphan Biovitrum Proposes No Dividend For 2025
Sweden's Sobi Q4 revenue misses estimates